AUTO-CHECK: Molecular determinants of autoimmunity and immune related adverse events in advanced cancer participants treated with immune checkpoint inhibitors
Latest Information Update: 24 Nov 2021
At a glance
- Drugs Durvalumab (Primary) ; Nivolumab (Primary) ; Tremelimumab (Primary)
- Indications Brain cancer; Cancer; Endometrial cancer; Lung cancer; Mesothelioma; Non-small cell lung cancer; Renal cancer; Uterine cancer
- Focus Adverse reactions
- Acronyms AUTO-CHECK
- 24 Nov 2021 New trial record